It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles
- A loving pet owner sweetly recreated a 20-year old picture of him with his childhood cat before havi2024-05-07
China's 5G phone shipments top 167 mln in 2020: report
Consumers experience 5G mobile phones at a business hall of China Mobile Beijing Branch in Beijing,2024-05-07UC Berkeley to host conference on gene
The University of California, Berkeley, said Tuesday it will host a two-day conference to discuss p2024-05-07China's current account surplus remains in reasonable range
Video PlayerCloseBEIJING, Sept. 28 (Xinhua) -- China's current account surplus remained in a reasona2024-05-07What we learned from local votes ahead of looming UK general election
LONDON (AP) — Millions of voters in England cast ballots Thursday in an array of local elections, th2024-05-07China cuts 88 bln yuan in logistics costs in 2017
China reduced logistics costs by more than 88 billion yuan (13.4 billion U.S. dollars) in 2017, the2024-05-07
atest comment